Clinical Update (02/2007)
A brief summary of recent clinical developments impacting the medical device industry, including limb regeneration, NIH's research plan for Type I diabetes, heart failure and statins; and new glaucoma research.
You may also be interested in...
NicOx plans to retain at least some rights to its late-stage osteoarthritis candidate. But can an R&D focused biotech do primary care?
Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.
If the FDA's decision in September 2005 to ask for additional safety data on the dual PPAR agonist muraglitazar (Pargluva, from Bristol-Myers Squibb and Merck) virtually killed development of all such compounds, the data presented less than a year later at the American Diabetes Association annual meeting has Big Pharma excited again about the potential for new classes of diabetes drugs.